March 16, 2017
Cephalon Inc. has settled a whistleblower's False Claims Act suit over the company's alleged off-label promotion of its narcolepsy drug Provigil, according to an order filed in Pennsylvania federal court Thursday.
February 02, 2016
A Pennsylvania federal judge agreed Tuesday to peel a year's worth of claims from consolidated litigation over Cephalon Inc.'s alleged off-label promotion of its narcolepsy drug Provigil, finding that the federal government's decision not to intervene in the False Claims Act case triggered a six-year statute of limitations.
July 30, 2015
A Pennsylvania federal judge Thursday denied a bid by Cephalon Inc. to dismiss claims in a False Claims Act suit relating to off-label marketing of its drug Provigil, saying a recent high court ruling did not support Cephalon's assertion that similar claims in a related whistleblower suit barred the instant claims.
July 21, 2015
A Pennsylvania federal judge on Tuesday refused Cephalon Inc.'s bid to dismiss claims in a False Claims Act dispute alleging the pharmaceutical company improperly promoted drugs for off-label uses, finding the relators properly stated a claim concerning its corporate integrity agreement.
April 15, 2015
A Pennsylvania federal judge pared charges Wednesday from a False Claims Act case alleging pharmaceutical company Cephalon Inc. improperly promoted drugs for off-label uses, saying some state law claims could not be prosecuted but allowing key federal charges to continue.
March 31, 2015
Pharmaceutical company Cephalon Inc. urged a Pennsylvania federal judge on Tuesday to nix a pair of whistleblower suits accusing it of spurring false reimbursement claims to the government through a scheme to promote three of its drugs off-label.
November 06, 2014
Cephalon Inc. told a Pennsylvania federal court Wednesday that two remaining False Claims Act cases against it for off-label promotion should not be consolidated, arguing that since the relators' Fentora claims have been dismissed, they no longer share common matters of fact.
October 10, 2014
A Pennsylvania federal judge on Thursday trimmed allegations from two False Claims Act complaints accusing Cephalon Inc. of promoting painkiller Fentora and other drugs for off-label uses, finding that whistleblowers parroted earlier allegations.